Free public lecture: “How can I avoid getting breast cancer?”

SAN ANTONIO (January 4, 2011) — Peter Ravdin, M.D., Ph.D., director of the Comprehensive Breast Health Clinic at the UT Health Science Center San Antonio’s Cancer Therapy & Research Center (CTRC), will lead a free discussion on breast health and breast cancer prevention Jan. 13.

Dr. Ravdin, a nationally recognized oncologist who contributed to recent important findings on combined hormone replacement therapy in the Women’s Health Initiative study, will talk about new and encouraging developments in the areas of breast cancer screening and prevention.

“There are ways that many women can more than halve their risk of getting breast cancer,” Dr. Ravdin said. “Combinations of diet and exercise, and also taking some medications (and avoiding some others) can have major protective effects. In addition, screening mammography can help by making sure that breast cancer is discovered when it is most treatable, and when the treatments can be the simplest but still very effective.”

The second in the CTRC’s monthly lecture series for cancer prevention and treatment, the discussion is free and open to the public.

“Breast cancer deaths are decreasing,” Dr. Ravdin said. “Learn how to fully benefit by being part of these positive changes.”
The presentation will be Thursday, January 13, from 6 p.m. to 7:30 p.m. at the CTRC, 7979 Wurzbach, in the Mabee conference room on the fourth floor of the Grossman Building. Refreshments will be provided. To make reservations (which are encouraged but not required) and for more information, call 450-1152.

The Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio is one of the elite academic cancer centers in the country to be named a National Cancer Institute (NCI) Designated Cancer Center, and is one of only four in Texas. A leader in developing new drugs to treat cancer, the CTRC Institute for Drug Development (IDD) conducts one of the largest oncology Phase I clinical drug programs in the world, and participates in development of cancer drugs approved by the U.S. Food & Drug Administration. For more information, visit

Share This Article!